NCT06128382View on ClinicalTrials.gov

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

July 8, 2024

Study Completion Date

November 29, 2024

Conditions
Coronavirus
Interventions
BIOLOGICAL

OVX033

One single administration intramuscularly on Day 1

BIOLOGICAL

Saline solution

One single administration intramuscularly on Day 1

Trial Locations (1)

Unknown

CIC Cochin Pasteur CIC 1417 Hôpital Cochin, Paris

Sponsors

Lead Sponsor

Osivax
All Listed Sponsors
collaborator

CIC 1417 Cochin Pasteur Hôpital Cochin Paris France

UNKNOWN

lead

Osivax

INDUSTRY

NCT06128382 - First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers | Biotech Hunter | Biotech Hunter